Cidofovir contraindications
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Contraindications
Initiation of therapy with VISTIDE is contraindicated in patients with a serum creatinine > 1.5 mg/dL, a calculated creatinine clearance ≤ 55 mL/min, or a urine protein ≥ 100 mg/dL (equivalent to ≥ 2+ proteinuria).
VISTIDE is contraindicated in patients receiving agents with nephrotoxic potential. Such agents must be discontinued at least seven days prior to starting therapy with VISTIDE.
VISTIDE is contraindicated in patients with hypersensitivity to cidofovir.
VISTIDE is contraindicated in patients with a history of clinically severe hypersensitivity to probenecid or other sulfa-containing medications.
Direct intraocular injection of VISTIDE is contraindicated; direct injection of cidofovir has been associated with iritis, ocular hypotony, and permanent impairment of vision.[1]
References
- ↑ "http://www.accessdata.fda.gov/drugsatfda_docs/label/1999/020638s003lbl.pdf" (PDF). External link in
|title=
(help)
Adapted from the FDA Package Insert.